Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07902544

Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma

Conditions: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 717
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Summary

Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC). However, the station-specific distribution of residual lymph node metastasis after NCIT remains incompletely characterized, and whether a pathologic complete response of the primary tumor implies nodal clearance is unclear. This single-center retrospective cohort study included consecutive patients with middle thoracic ESCC who underwent esophagectomy with lymphadenectomy (at least 15 nodes retrieved) between June 2012 and June 2025. Station-specific lymph node metastasis rates were analyzed in the NCIT group (n = 272) according to residual pathologic T category (ypT), and in the upfront surgery group (n = 445) according to pathologic T category (pT). The two groups followed different clinical pathways and were not randomized; between-group comparisons are descriptive only and no causal inference is intended. The study aims to provide an anatomic basis for surgical planning and postoperative risk stratification in middle thoracic ESCC.

Eligibility Criteria

Inclusion Criteria: 1. Age 18 years or older at the time of surgery. 2. Tumor located in the middle thoracic esophagus. 3. Histologically confirmed esophageal squamous cell carcinoma. 4. Esophagectomy with lymphadenectomy performed. 5. At least 15 lymph nodes dissected and examined. 6. Surgery performed at the study center between June 2012 and June 2025. Exclusion Criteria: 1. Adenocarcinoma, small-cell carcinoma, or other histologic subtypes. 2. Concomitant malignant tumors. 3. Incomplete medical records.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07902544). StuddyBuddy aggregates publicly available trial information.